Rockwell Medical Q2 Sales Rise 11%, Gross Margin Expands to 18%; Reiterates 2026 Guidance
RMTI sits 54% above its 52-week low of $4.885.
Summary
Rockwell Medical reported Q2 2026 net sales of $17.8M, up 11% YoY, with gross margin expanding to 18% and positive operating cash flow. The company reiterated its full-year 2026 guidance.
Key Events · Earnings and Guidance · RMTI
-
Q2 Revenue Up 11%
Net sales of $17.8M for Q2 2026, up from $16.1M in Q2 2025, driven by new customers in the Western U.S. and increased purchasing from existing customers.
-
Gross Margin Expands to 18%
Gross profit rose 30% to $3.2M, with gross margin improving to 18% from 16% a year ago, reflecting lower manufacturing costs and higher volume.
-
Positive Operating Cash Flow
Generated $2.1M in cash flow from operations in Q2, increasing cash and investments to $24.8M at June 30, 2026.
-
Net Loss Narrows
Net loss improved to $1.2M from $1.5M in Q2 2025; Adjusted EBITDA was ($0.2M), in line with the prior year.
Analysis · RMTI · Life Sciences
Rockwell Medical delivered a solid Q2 with revenue up 11% year-over-year, gross margin expanding to 18%, and positive operating cash flow. The company reiterated its full-year guidance, signaling confidence in its turnaround. The results show improving profitability and a strengthening balance sheet, though the company remains unprofitable on a GAAP basis.
At the time of this filing, RMTI was trading at $7.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $4.89 to $21.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.